Background/Aims: This study aimed to investigate whether Salvianolic acid A (Sal A) conferred cardiac protection against Arsenic trioxide (ATO)-induced cardiotoxicity in H9c2 cells by inhibiting MAPK pathways activation. Methods: H9c2 cardiac cells were exposed before exposure to ATO. Cell viability was determined utilizing the MTT assay. The percentage Mitochondrial membrane potential ( were measured using an Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit. The apoptosis-related proteins and the MAPK signaling pathways proteins expression were Results: Sal A pretreatment increased cell viability, suppressed rate by enhancing endogenous antioxidative enzyme activity and ROS generation. Signal transduction studies indicated that Sal A suppressed the ATO-induced activation of the MAPK pathway. More importantly, JNK, ERK, and p38 inhibitors mimicked the cytoprotective activity of Sal A against ATO-induced injury in H9c2 cells by increasing cell viability, up-regulating Bcl-2 protein expression, and down-regulating both Bax and caspase-3 protein expression. Conclusion: Sal A decreases the ATO-induced apoptosis and necrosis of H9c2 cells, and the underlying mechanisms of this protective effect of Sal A may be connected with the MAPK pathways.
Introduction
Arsenicals have been used in traditional Chinese mineral medicine for approximately 2400 years. Arsenic trioxide (ATO) has recently been deemed as an effective form of antineoplastic therapy, especially for relapsed or refractory acute promyelocytic leukemia [1] . In 2000, the Food and Drug Administration approved ATO application as a treatment for APL [2] . However, the clinical application of ATO is limited by its cardiotoxicity, as it induces T-wave changes, QT prolongation, torsades de pointes, and sudden cardiac death in humans unavailable. DNA fragmentation, excessive reactive oxygen species (ROS) generation, intracellular calcium overload, cardiac ion channel changes, and apoptosis are strongly related to ATO-induced cytotoxicity [6] [7] [8] . ROS overproduction is a crucial toxic mechanism of ATO. Therefore, we hypothesized that the application of antioxidant phytochemicals could prevent ATO-induced cardiotoxicity. Chinese herbal medicine is a good source of potent, safe, and affordable bioactive compounds for cardioprotection. Therefore, an antioxidant agent that can lower ATO cardiotoxicity and improve clinical curative effects from traditional Chinese medicine is indispensable.
Radix salviae Miltiorrhiza is a multi-purpose medicinal plant that has been commonly used for cardiovascular diseases for centuries. Salvianolic acids have been proven to possess effective antioxidants and radical scavenging capabilities because of their polyphenolic structure [9] . Salvianolic acids also protect cardiomyocytes against drug-induced cardiotoxicity through their ROS scavenging ability. In an animal model of doxorubicininduced toxicity, salvianolic acids protected the myocardium by reducing oxidative stress [10] . Among the salvianolic acids, salvianolic acid A (Sal A) has the most potent antioxidant lipid peroxidation in damaged cardiac tissues of an ischemia/reperfusion injury model [12] . Furthermore, intravenous administration of Sal A markedly attenuates cardiac dysfunction and myocardial injury caused by isoproterenol and enhances mitochondrial respiratory whether Sal A can prevent ATO-induced cardiotoxicity. A recent study associated arsenicinduced cardiac cell death with MAPK activation [14] . Therefore, whether Sal A activates The present study aimed to determine the protective effect of Sal A against ATO-induced cardiotoxicity in H9c2 cells and explain its potential molecular mechanisms related to the MAPK pathway.
Materials and Methods

Chemicals and materials
Sal A (purity > 98%; molecular structure shown in Fig. 1 ) was purchased from Shanghai Winherb Medical S & T Development Co., Ltd. (Shanghai, China). ATO was obtained from Harbin YI-DA Pharmaceutical Ltd. (Harbin, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The kits for testing the lactate dehydrogenase (LDH) and malondialdehyde (MDA) contents and the superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-PX) activities were obtained from Nanjing Jiancheng Institute of Biological Engineering assay kits were acquired from BioVision (CA, USA). An annexin V/propidium iodide (PI) apoptosis detection kit was obtained from Invitrogen (Eugene, OR, USA). All primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from CWbiotech (Beijing, China). PD98059, SB203580 and SP600125 were purchased from Selleckchem (Houston, TX, USA). All chemical reagents were at least of analytical grade.
at an appropriate density in accordance with the experimental design and then grown for 36 h before the experiment. H9c2 cells were pretreated with the for 24 h. 
Cell viability analysis
Cell viability was measured using the MTT assay, as previously reported [16] . In brief, H9c2 cells were seeded in 96-well plates at a density of 1×10 4 cells/well. After 4 h of pretreatment with different doses Subsequently, 1 mg/mL MTT solution was added to each well, and the cells were incubated for 3-4 h at 37 °C. The supernatant was removed, and the insoluble MTT-formazan salt in each well was then dissolved in Sunrise, Austria).
LDH release assay
H9c2 cells were seeded in 6-well plates at 3×10 5 cells/well. The cells were pretreated with different concentrations of Sal A for 4 h before ATO was added in place of Sal A. After incubation for 24 h, the supernatant was collected to measure LDH release with an LDH assay kit according to the manufacturer's instructions.
FITC-Annexin V/PI apoptosis assay
The percentage of early apoptosis and necrosis was measured using a FITC-Annexin V/PI apoptosis drug treatment, the cells were harvested, washed twice with cold phosphate buffered saline (PBS), and then incubated with 5 µL of FITC-Annexin V and 1 µL of PI working solution (100 µg/mL) for 15 min in the dark at (FACSCalibur, BD Biosciences, CA, USA).
Autophagy detection
Detection Kit(Enzo Life Sciences). H9c2 cells incubated with different concentrations of ATO for 24 h or buffer (1 µL of reagent per 4 mL of 1× assay buffer). Incubate the cells for 30 min at room temperature Biosciences, CA, USA).
Measurement of mitochondrial membrane potential(
JC-1 (Invitrogen, USA) was used to detect the mitochondrial transmembrane potential changes caused the dark for 30 min at 37 °C following the manufacturer's instructions. Cells were washed twice with PBS
Generation of ROS
To explore the effect of Sal A on the intracellular and mitochondrial ROS levels, cells were pretreated were harvested and washed with 1× wash buffer. The cells were centrifuged at 400×g for 5 min at room temperature, and the supernatant was discarded. Intracellular ROS levels were measured using an ImageLife Sciences, Farmingdale, NY, USA). The cells were resuspended in 400 mL of the 25 mM carboxy-H2DCFDA
(Invitrogen, Molecular Probes). After treatment, the cells were suspended in warm PBS and incubated with
Measurement of the activities of SOD, CAT and GSH-Px
H9c2 cells were cultured in 6-well plates with 3×10 5 cells/well. After treatment, the cells were collected to measure the SOD, CAT, and GSH-Px activities with the corresponding detection kits according to the manufacturer's instructions.
Western blot analysis
24 h. Then, the cells were harvested, washed with PBS, and lysed for 30 min on ice using mammalian protein
The mitochondrial and cytosolic fractions were separated via a Cell Mitochondrial Isolation Kit (Beyotime, Haimen, China) according to the manufacturer's instructions. The protein concentration was measured with a BCA kit (Pierce Corporation, Rockford, IL, USA). Equal amounts of protein were fractionated using 10% sodium dodecyl sulfate polyacrylamide gels and electrotransferred onto nitrocellulose membranes (Millipore Corporation, Bedford, MD, USA) in Tris-glycine buffer at 100 V for 55 min in an ice box. Membranes were blocked for at least 2 h in 5% skim milk at room temperature and then incubated overnight with the primary antibodies (1:200) at 4 °C. After washing with Tris-buffered saline and Tween 20 (TBST) for 30 min, the membranes were incubated with the appropriate HRP-conjugated secondary antibodies for 2 h at room temperature. The membranes were washed three times for 30 min on a shaking table and then visualized with enhanced chemiluminescence solution. The different protein expression levels were determined using Molecular Imager Lab (Bio-Rad, USA).
Statistical analysis
The data were expressed as the mean ± SD of at least three independent experiments. Statistical comparisons between different groups were performed using a one-way ANOVA or the Student-NewmanKeuls method with GraphPad Prism 5.0 (SPAA, Inc., Chicago, USA). A value of p < 0.05 was considered
Results
Effects of Sal A on the viability of H9c2 cells
We initially evaluated the general toxicity of ATO. Cell viability was measured via the MTT assay. The cells were treated with a series of ATO concentrations (2.5, 5, 10, 20, and 40 compared with that in the control group; similar observations were made in a previous report A on H9c2 cells were then evaluated. After treatment with various concentrations (2.5-10
The capacity of Sal A to protect against ATO-induced H9c2 cellular injury was assessed. H9c2 cells were pretreated with the indicated Sal A concentrations for 4 h and then washed 
Effects of Sal A on ROS production and the activities of SOD, CAT, and GSH-Px
Excess generation of ROS during cell injury leads to cellular damage and apoptosis [18] .
control, whereas Sal A pretreatment attenuated the ATO-induced ROS generation in H9c2 cells in a dose-dependent manner. The intracellular accumulation of superoxide was estimated using MitoSOX TM Red, which selectively targets the mitochondria, where it is oxidized by to H 2 the ATO-induced mitochondrial ROS level increase (Figs. 6B) . These results indicate that ROS generation is involved in the protection by Sal A against ATO-induced cell injury. We measured the activities of SOD, CAT, and GSH-Px to determine the endogenous antioxidant capacity of H9c2 cells. As shown in Fig. 6C , ATO decreased the SOD, CAT, and GSH-Px activities, but Sal A pretreatment effectively reversed this effect in a dose-dependent manner. These results indicate that Sal A protects cells against oxidative stress injury by enhancing the antioxidant capacity of the cells.
Sal A modulated the expressions of apoptosis-related proteins in ATO-treated H9c2 cells
Western blot analysis was performed in H9c2 cells to investigate the protective mechanism of Sal A pretreatment on apoptosis regulation after ATO exposure. The Bcl-2 family of proteins, including Bcl-2, Bax, Bad, and Bcl-xl, plays an important role in ATOinduced cardiomyocyte apoptosis [19] . As shown in Fig. 7 , ATO treatment decreased Bcl-2 cell viability and the Bcl-2/Bax ratio, and decreased the ATO-induced expression of cleaved caspase-3. These results suggest that the protective effect of Sal A against ATO-induced apoptosis in H9c2 cardiomyocytes partially relies on the inhibition of MAPK signaling pathways.
Discussion
promyelocytic leukemia (APL) [22, 23] . Despite its remarkable effects on certain cancer types, ATO has adverse effects, such as cardiac toxicity; thus, its clinical applications are restricted [24] [25] [26] . ATO cardiotoxicity is known to proceed by As 3+ proteins, thereby damaging the mitochondrial respiratory chain and generating excessive ROS, eventually leading to myocardial cell apoptosis [27, 28] . In line with previous reports, we showed that ATO treatment can increase ROS production and decrease antioxidant enzyme activity in cardiomyocytes. Therefore, ATO induces oxidative stress in myocardial cells by producing ROS and inhibiting the intrinsic protective antioxidant capacity [29] [30] [31] . Consequently, a compound that can decrease ROS overproduction and also prevent cardiomyocyte apoptosis is of great interest to improve the adverse effects of ATO. Considerable evidence has revealed that Sal A is effective for cardiovascular therapy and is a potent antioxidant against peroxidative damage to biomembranes [32, 33] . In the current study, Sal A pretreatment for 4 h attenuated ATO-induced H9c2 cardiomyocyte injury, increased cell viability, decreased LDH leakage, and modulated the cardiomyocyte redox state by increasing the activities of antioxidant enzymes (GSH-Px, SOD, and CAT) that were inhibited after ATO treatment.
ATO-induced oxidative stress leads to mitochondrial dysfunction and cardiomyocyte apoptosis, both of which contribute to myocardial injury development [34] . The hyperpolarization of damaged mitochondrial membranes initiates opening of the MPTP, mitochondrial translocation of Bcl-2 and Bax, and release of cyt-c. In contrast, Sal A pretreatment strongly attenuated ATO-induced mitochondrial damage. Numerous studies have also suggested that the Bcl-2/Bax ratio determines the cellular threshold for apoptosis [35] . Sal A pretreatment enhanced anti-apoptotic Bcl-2 and Bcl-xl expression levels but reduced those of pro-apoptotic Bax and Bad. Caspase-3 is thought to initiate cell apoptosis. Caspase-3 leads to DNA fragmentation and other morphological changes that are consistent with cell death [36] . PARP is an important indicator of caspase-3 activation [37] . In the pretreatment reversed this effect. This result indicates that the anti-apoptotic effect of Sal A is mediated by caspase-3. Based on the data, Sal A might provide protection by balancing the Bcl-2 and Bax ratio, preventing the mitochondria from releasing cyt-c and ultimately inhibiting caspase-3 expression. The MAPK pathways, which include ERK1/2, JNK, and p38 MAPK, are vital mediators of oxidative stress-induced apoptosis. MAPK activation is involved in ATO-induced tumor cells and cardiac cell death [14, 38, 39] . Consequently, we hypothesized that the protective effect of Sal A against ATO-induced apoptosis in H9c2 cells is related to MAPK signaling cascades. As expected, Sal A pretreatment inhibited the phosphorylation of JNK, ERK1/2, and p38. To assess whether the protective effect of Sal A is related to MAPK inhibition, we blocked the MAPK signaling pathway with a JNK inhibitor (SP98059), a p38 inhibitor (SB203580), and an ERK inhibitor (PD98059). The pretreatment of cells with these inhibitors alone had similar cardioprotective effects compared with Sal A. Therefore, Sal A may suppress ATOinduced cell apoptosis at least partially by modulating the MAPK signaling pathways.
The role of autophagy in ATO-induced cardiotoxicity remains controversial. However, our results are similar to those found for ATO exposure in HL-1 mouse trial cardiomyocytes [40] ; only a slight activation of autophagy was observed, thereby suggesting the differential reactions of apoptosis and autophagy to ATO toxicity.
Conclusion
as shown by increased cell viability, decreased LDH leakage, enhanced antioxidant enzyme expression, and up-regulated Bcl-2 expression in cells. The protective effect of Sal A against ATO-induced H9c2 cell apoptosis is dependent on the MAPK signaling pathway. These results ATO-induced cardiotoxicity.
Nevertheless, this study is in its initial stages, and the results of the in vitro cell necessary to further explore the mechanisms of Sal A against ATO-induced cardiotoxicity.
